|
Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV Clinical research trials and Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV. Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV clinical trial. Human subjects often obtain the finest healthcare possible for their Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV  Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: HIV can be transmitted from an HIV infected mother to her infant through her breast milk. The purpose of this study is to determine whether giving infants of HIV infected mothers the anti-HIV drug nevirapine (NVP) for six weeks will reduce the risk of HIV transmission.
Details: The use of antiretroviral therapy during late pregnancy, intrapartum, and immediately postpartum prevents a high proportion of vertical transmission. Potential means of decreasing HIV transmission through breastfeeding, along with the risks and benefits of early weaning, need to be further evaluated. The potential impact of early weaning interventions on the breastfeeding habits of the HIV uninfected population needs to be considered as well. This study seeks to identify a way to make breastfeeding safe for HIV infected women who choose to breastfeed. A single dose of NVP given to infants of HIV infected mothers appears to provide some protection against vertical transmission. NVP’s long half-life allows simple dosing, making it more feasible and affordable to implement in a developing country. This study will determine whether extending the NVP dosing to six weeks will significantly decrease transmission during the first several months of breastfeeding.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - HIV infection, documented on two separate specimens - Estimated gestational age at enrollment of 32 weeks or more as indicated by last menstrual cycle and fundal height - Permanent residency in Addis Ababa - Plan to deliver at a hospital affliated with the study (Tikur Anbessa Hospital, Gandhi hospital, or St. Paul's Hospital) - Hemoglobin >= 7.5 gm/dl within 4 weeks prior to study entry - Serum glutamic pyruvic transaminase (SGPT) < 5 times upper limit of normal within 4 weeks prior to study entry - Serum creatinine < 1.5 mg/dl within 4 weeks prior to study entry - Consent form signed by the mother and, when possible, by the father, prior to the onset of labor
Total Enrollment: 1912
Location and Contact Information:
Tikur Anbessa Hospital *Recruiting*
Addis Abeba, ,
Ethiopia
Recruiting Abubaker Bedri 251 1 525816
Additional Information:
Study ID Numbers: 5R01AI038576-05; NIGAT Project
Study Start Date: February 2001
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00074399
Other Hiv Infections Studies:
1. The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.
2. Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers
3. An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
4. Rifabutin Therapy for the Prevention of Mycobacterium avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
5. Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Addis Abeba Clinical Trials
Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
|
|
|
|
|
|
|
|
